*ST HILE’s controlling shareholder changed to actual controller Zhang Haiming: Father and daughter take over all 34.70% shares for 600 million yuan.

Source: Hile Bio-Technology Acquisition Report

DentalGoodNews｜On August 14, 2026, SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. (hereinafter referred to as "*ST HILE") released an acquisition report. The announcement shows that the company's controlling shareholder, Shanghai Haoyuan Venture Capital Investment Development Co., Ltd. (hereinafter referred to as "Shanghai Haoyuan"), plans to transfer all of its 226,197,938 unrestricted tradable shares (accounting for 34.70% of the total share capital) to the company's ultimate controller Zhang Haiming and his concerted action person Zhang Yue through agreement transfer.

The transaction price per share is RMB 2.655 yuan, with a total transfer consideration of RMB 600,555,525.40. Among this, Zhang Haiming will acquire 158,338,557 shares (accounting for 24.29%), paying RMB 420,388,868.84; Zhang Yue will acquire 67,859,381 shares (accounting for 10.41%), paying RMB 180,166,656.56. Upon completion of the transaction, Shanghai Haoyuan will no longer hold shares in the company, and Zhang Haiming will replace it as the company's direct controlling shareholder.

Source: Hile Bio-Technology Acquisition Report

This transfer is conducted between different entities controlled by the same ultimate controller. Zhang Haiming is the ultimate controller of *ST HILE, Zhang Yue is his daughter, and Chen Xiao is Zhang Yue's spouse; both are concerted action persons of Zhang Haiming. Before and after the transfer, the total number of shares controlled by the ultimate controller and his concerted action persons remains unchanged at 247,159,688 shares, accounting for 37.91%. Pursuant to Article 62, Paragraph (1) of the "Measures for the Administration of Acquisition of Listed Companies," the acquirer is exempted from increasing shareholding through a tender offer.

Source: Hile Bio-Technology 2025 Annual Report

*ST HILE stated in the announcement that this move is aimed at optimizing the shareholding structure and improving management efficiency. According to previous reports by DGN, HILE recorded a net loss of RMB 311 million in 2025 due to goodwill impairment, and has been subject to a delisting risk warning since May 6, 2026, with the stock abbreviation changed to "*ST HILE."

In its 2025 annual report, *ST HILE disclosed that the company has divested its animal health business, focused on its core oral business, and expanded into the full oral industry chain through the acquisitions of Zhejiang Zhuoshiyou Medical Device Co., Ltd. and Jinboli Dental Clinic. According to previous reports by DGN, the company had previously established a secondary management platform through its controlling subsidiary Ruisheng Biology to uniformly manage seven Jinboli dental chain stores located in Yangzhou and Changzhou.